| Document |
Document Title |
|
WO/2010/119875 |
Disclosed is a fused pyrrolopyridine derivative which is useful as an active ingredient for a pharmaceutical composition, in particular a pharmaceutical composition for prevention or treatment of diseases that are caused by undesirable c...
|
|
WO/2010/118699 |
High purified (2β,3α,5α,16β,17β) -2-(4-morpholinyl)-16-(1-pyrrolidinyl)-androstane-3,17-diol (formula III) or composition containing it and their use in preparing rocuronium bromide (formula I) are disclosed.
|
|
WO/2010/121225 |
The invention provides methods for the treatment or amelioration of disorders associated with undesired activity of protein kinase CK2, using compounds of Formula (I) that are potent, selective inhibitors of CK2, and pharmaceutical compo...
|
|
WO/2010/116673 |
Disclosed are a novel mitochondrial function-improving agent and a novel PGC-1α expression inducer. Specifically disclosed are a mitochondrial function-improving agent and a PGC-1α expression inducer, each of which comprises a lysine-s...
|
|
WO/2010/113225 |
The present invention provides a novel transdermal patch containing high concentration of riluzole and being able to administer transdermally and quantitatively the drug to the ALS patients having difficulties taking the drug orally. Fur...
|
|
WO/2010/113834 |
Disclosed is a novel and excellent method for preventing and/or treating cannabinoid-2 receptor-related diseases, which is based on an agonist action on cannabinoid-2 receptors. Specifically disclosed is a heterocyclic derivative mainly ...
|
|
WO/2010/112091 |
Compounds of formula (I) wherein R1, R2, R3, X, and Y are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.
|
|
WO/2010/112093 |
Compounds of formula (I), wherein R1, R2, R3, X and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.
|
|
WO/2010/112092 |
Compounds of formula (I) wherein R1, R2, R3, R4, L1, and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.
|
|
WO/2010/108843 |
The present invention relates to the use of nitric oxide releasing derivatives of paracetamol for retarding or reversing muscular dystrophies such as Duchenne and Becker dystrophies.
|
|
WO/2010/109386 |
|
|
WO/2010/106295 |
The invention relates to decorin for increasing muscle mass, in particular in the treatment of muscular dystrophies.
|
|
WO/2010/108001 |
Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.
|
|
WO/2010/108001 |
Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.
|
|
WO/2010/104024 |
Disclosed is a piperazine compound represented by general formula (I) or a salt thereof. [In the formula, R1 represents an alkyl group having 1 to 6 carbon atoms; R2 represents any one selected from a hydroxy group, an alkyl group having...
|
|
WO/2010/095663 |
Disclosed is a compound represented by formula (I) or a salt thereof, which has GPR 119 agonist action and excellent medicinal effects useful for prevention/treatment of diabetes, adiposis and the like. In the formula, P represents a sub...
|
|
WO/2010/093784 |
The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. I...
|
|
WO/2010/093322 |
The present invention relates to methods for identifying therapeutic agents capable of modulating the activity of the IGF2 repressor ZBED6 for use in growth promotion,wound healing, angiogenesis, inhibition of muscle wasting, and treatme...
|
|
WO/2010/093784 |
The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. I...
|
|
WO/2010/092966 |
Disclosed is a novel compound having P2X3 or P2X2/3 receptor antagonistic effect. Specifically disclosed is a compound represented by formula (I). (In the formula, (a) Ra and Rb combine together to form =Z, and Rc is a group represented...
|
|
WO/2010/087306 |
Disclosed is a novel anti-neurodegenerative disease agent. The anti-neurodegenerative disease agent comprises a compound represented by general formula (1) as an active ingredient. In general formula (1), R1 to R3 independently represen...
|
|
WO/2010/086040 |
Compounds of formula (I) wherein R1, R2, R3, R4, R5, L1, L2, m, and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.
|
|
WO/2010/087313 |
Disclosed is a novel neurite elongation stimulator. The neurite elongation stimulator comprises a compound represented by general formula (1) as an active ingredient. In general formula (1), R1 to R3 independently represent a hydrogen a...
|
|
WO/2010/087244 |
A novel low-molecular compound having an immunosuppressive action. The compound is a compound having general formula (I) or a pharmacologically acceptable salt thereof. [In the formula, the substituents are defined as shown below: R1 and...
|
|
WO/2010/084999 |
Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases, which contain the substances (for example, anti-galectin-9 antibody, anti-Tim-3 antibody, RNA and DNA aptamers and low molecular substances) blocki...
|
|
WO/2010/081862 |
The present invention relates to the use of a polyamine or a salt, solvate, or derivative thereof, such as spermine or spermidine for the treatment or prevention of a life threatening condition, such as multiple organ failure, in a criti...
|
|
WO/2010/081862 |
The present invention relates to the use of a polyamine or a salt, solvate, or derivative thereof, such as spermine or spermidine for the treatment or prevention of a life threatening condition, such as multiple organ failure, in a criti...
|
|
WO/2010/079668 |
Disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (In the formula, R1, R2, R2', R4, R5, R6, R7, R8 and R8' each represents a hydrogen atom or the like; and R3 represents a hydrogen...
|
|
WO/2010/080581 |
|
|
WO/2010/081070 |
The invention relates to novel crystalline forms of (2RS)-1 -(4-ethylphenyl)-2-methyl-3- piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention i...
|
|
WO/2010/080455 |
This invention relates to a hydrochloride, malafe, oxalate and tartrate salt forms of 1-(4- { 1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}
-2-ethyl-benzyI)-azetidine- 3-carboxylic acid (Compound I), to pharmaceutical comp...
|
|
WO/2010/081070 |
The invention relates to novel crystalline forms of (2RS)-1 -(4-ethylphenyl)-2-methyl-3- piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention i...
|
|
WO/2010/075611 |
A composition comprising a proanthocyanidin, a proteolytic enzyme and a substance derived from Aloe Vera and/or from a plant of the Agave species, the composition being free of papain. Use of the composition for improving athletic perfor...
|
|
WO/2010/077686 |
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorder...
|
|
WO/2010/074284 |
By searching for a number of various compounds having an activity of inhibiting IL-12/IL-23 production, provided are a medicinal composition and a drug for treating or preventing a disease relating to the hyperproduction of IL-12/IL-23, ...
|
|
WO/2010/075263 |
Compounds and methods for enhancing erythropoiesis are disclosed. The compound comprises a chemical structure of the formula (I) indicated below, in which R is a glycosyl group. In addition to having an erythropoiesis effect, the compoun...
|
|
WO/2010/073531 |
Provided is a muscle-building agent comprising a whey protein hydrolyzate having a muscle increasing effect which is highly safe, an aqueous solution of which is highly transparent and which can be used in various products without limita...
|
|
WO/2010/075287 |
The present invention relates generally to alkyne containing pharmaceutical agents, and in particular, to phenylethynyl-thiophene based metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of...
|
|
WO/2010/075263 |
Compounds and methods for enhancing erythropoiesis are disclosed. The compound comprises a chemical structure of the formula (I) indicated below, in which R is a glycosyl group. In addition to having an erythropoiesis effect, the compoun...
|
|
WO/2010/075287 |
The present invention relates generally to alkyne containing pharmaceutical agents, and in particular, to phenylethynyl-thiophene based metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of...
|
|
WO/2010/070094 |
Description of antigen binding proteins, such as antibodies, which bind to myostatin, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture...
|
|
WO/2010/069949 |
The invention provides compounds of Formula (I) for the treatment of multiple sclerosis and other diseases.
|
|
WO/2010/069684 |
Compounds of formula (I): wherein R1, R2, X1, and X2 are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.
|
|
WO/2010/071794 |
This invention relates to a novel crystalline form (Form A) of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-
ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this c...
|
|
WO/2010/068264 |
The invention provides method and composition for alleviating one or more symptoms associated with a medical condition mediated by one or more of a cyclooxygenase, a pro- inflammatory cytokine, and a pro-inflammatory enzyme. The method i...
|
|
WO/2010/068264 |
The invention provides method and composition for alleviating one or more symptoms associated with a medical condition mediated by one or more of a cyclooxygenase, a pro- inflammatory cytokine, and a pro-inflammatory enzyme. The method i...
|
|
WO/2010/064248 |
Use of an agent which upregulates an activity or amount of miRNA-9 or miRNA-9* is disclosed for the preparation of a medicament for the treatment of a motor neuron disease (MND).
|
|
WO/2010/064707 |
Disclosed is a compound which has an excellent S1P1 agonistic activity and is particularly useful as an active ingredient for a prophylactic and/or therapeutic agent for diseases induced by undesirable lymphocyte infiltration or diseases...
|
|
WO/2010/064597 |
A compound represented by formula (I) or a salt thereof. In formula (I), the symbols are as defined in the description.
|
|
WO/2010/064248 |
Use of an agent which upregulates an activity or amount of miRNA-9 or miRNA-9* is disclosed for the preparation of a medicament for the treatment of a motor neuron disease (MND).
|
